A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

NCT02580058 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

566

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

BIOLOGICAL: avelumab
DRUG: PLD

Sponsor

Pfizer